.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,337,824

« Back to Dashboard
Patent 8,337,824 protects VELTASSA and is included in one NDA.

This patent has thirty-two patent family members in eighteen countries.

Summary for Patent: 8,337,824

Title:Linear polyol stabilized polyfluoroacrylate compositions
Abstract: The present invention is directed to compositions of a linear polyol and a salt of a crosslinked cation exchange polymer comprising a fluoro group and an acid group. These compositions are useful to bind potassium in the gastrointestinal tract.
Inventor(s): Albrecht; Detlef (Saratoga, CA), Burdick; Michael (Los Altos, CA), Chang; Han-Ting (Livermore, CA), Charmot; Dominique (Campbell, CA), Chidambaram; Ramakrishnan (Pleasanton, CA), Connor; Eric (Los Gatos, CA), Halfon; Sherin (Palo Alto, CA), Huang; I-Zu (Mountain View, CA), Liu; Mingjun (Campbell, CA), Mills; Jonathan (San Jose, CA), Struver; Werner (Leverkusen, DE)
Assignee: Relypsa, Inc. (Santa Clara, CA)
Application Number:12/545,810
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Use;
Patent Metrics:
Source: PatentQuant.com
Field: Pharmaceuticals
Back Citations: 62nd percentile
Forward Citations: 1st percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Relypsa Inc
VELTASSA
patiromer sorbitex calcium
POWDER;ORAL205739-001Oct 21, 2015RXNo8,337,824► subscribeY TREATMENT OF HYPERKALEMIA
Relypsa Inc
VELTASSA
patiromer sorbitex calcium
POWDER;ORAL205739-002Oct 21, 2015RXNo8,337,824► subscribeY TREATMENT OF HYPERKALEMIA
Relypsa Inc
VELTASSA
patiromer sorbitex calcium
POWDER;ORAL205739-003Oct 21, 2015RXYes8,337,824► subscribeY TREATMENT OF HYPERKALEMIA
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,337,824

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia2009282721► subscribe
BrazilPI0917853► subscribe
Canada2735058► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc